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ABSTRACT
Background: The characterization of uncertainty is critical in cost-
effectiveness analysis, particularly when considering whether additional
evidence is needed. In addition to parameter and methodological uncer-
tainty, there are other sources of uncertainty which include simpliﬁcations
and scientiﬁc judgments that have to be made when constructing and
interpreting a model of any sort. These have been classiﬁed in a number of
different ways but can be referred to collectively as structural uncertainties.
Materials and Methods: Separate reviews were undertaken to identify
what forms these other sources of uncertainty take and what other
forms of potential methods to explicitly characterize these types of
uncertainties in decision analytic models. These methods were demon-
strated through application to four decision models each representing
one of the four types of uncertainty.
Results: These sources of uncertainty fall into four general themes:
1) inclusion of relevant comparators; 2) inclusion of relevant
events; 3) alternative statistical estimation methods; and 4) clinical
uncertainty.
Two methods to explicitly characterize such uncertainties were identi-
ﬁed: model selection and model averaging. In addition, an alternative
approach, adding uncertain parameters to represent the source of uncer-
tainty was also considered.
The applications demonstrate that cost-effectiveness may be sensitive to
these uncertainties and the methods used to characterize them. The value of
research was particularly sensitive to these uncertainties and the methods
used to characterize it. It is therefore important, for decision-making
purposes, to incorporate such uncertainties into the modeling process.
Conclusion: Only parameterizing the uncertainty directly in the model
can inform the decision to conduct further research to resolve this source
of uncertainty.
Keywords: decision analysis, model structure, uncertainty.
Introduction
Decision analytic models are increasingly being used to inform
policy questions regarding the optimum allocation of health-care
expenditures [1–3] and to represent an explicit way of synthesiz-
ing information on the costs and outcomes of the alternative
interventions of interest. A decision model can help to inform not
only the adoption of health technologies but also priorities for
future research using expected value of information (EVI)
approaches [4,5].
The increased proﬁle of decision analysis means that, more so
than ever, there is a need for robust methods of analysis in the
assessment of technologies. The issue of appropriately character-
izing uncertainty is central to this process. Uncertainty is perva-
sive in cost-effectiveness analysis and exists because we can never
predict for certain what the mean costs and outcomes associated
with the use of a particular treatment will be. If the objective is
to maximize health, given a particular budget, then additional
evidence which can reduce this uncertainty will provide more
precise estimates and lead to better decisions which will overall
improve health outcomes.
There are a number of sources of uncertainty that are relevant
to estimating the cost-effectiveness of a particular intervention, for
example, uncertainty in the treatment effects or cost inputs, the
type of model used, and the applicability or generalizability of
these results to a particular decision-maker. The sources of uncer-
tainty have been distinguished in different ways but are commonly
described as parameter, methodological and structural [6]. Param-
eter uncertainty relates to the fact that we do not know the true
value of a given parameter such as relative risk. Methodological
uncertainty is somewhat different and can be deﬁned as disparities
in the choice of analytic methods that underpin an economic
evaluation [7], e.g., the perspective of the evaluation, which
governs what types of costs and outcomes are included [8]. Other
sources of uncertainty include the different types of simpliﬁcations
and scientiﬁc judgments that have to be made when constructing
and interpreting a model of any sort. These have been classiﬁed in
a number of different ways but can be referred to collectively as
structural uncertainties. Indeed, the term is often simply used to
classify those types of uncertainty that do not easily ﬁt into the
categories of parameter or methodological [9].
Within health technology assessment (HTA), analysts have
tended to focus almost entirely on quantifying and assessing the
impact of parameter uncertainty. As a consequence, methods
(such as sensitivity analysis and probabilistic sensitivity analysis)
for dealing with parameter uncertainty are becoming familiar
practice [4]. Many issues of methodological uncertainty have
been resolved through guidelines, encouraging the harmoniza-
tion of economic evaluation techniques [10]. Structural uncer-
tainty, however, has received relatively little attention, although
many guidelines of good modelling practice recognize the need to
explore the implications of alternative but plausible assumptions
[11–13].
This paper contributes toward an understanding of what
constitutes structural uncertainty, by reviewing how it is has been
deﬁned in the HTA literature. We then review currently available
methods and apply them to four case studies to demonstrate the
importance of these sources of uncertainty and the performance
of the methods available to characterize them.
Other Sources of Uncertainty
The term “structural uncertainty” is used here, as elsewhere, to
describe those other sources of uncertainty not characterized in
other ways (parameter or methodological). This broad deﬁnition,
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as “all other sources of uncertainty,” was used to identify
examples of structural uncertainty that have been described in
the HTA literature. A review of decision models commissioned
by the National Health Service (NHS) HTA program in the
period of 1997–2005 was undertaken [9]. Further details of this
review are presented elsewhere [9].
Of the 241 published HTA reports, 90 (37%) include some
form of decision analytic model. Of these 13, structural and or
model uncertainties are identiﬁed [14–26]. Table 1 reports the
type of uncertainties identiﬁed and the methods applied to deal
with these in each of the separate reports.
The results of this review suggests that these other sources of
uncertainty (collectively described a structural) can be usefully
described as falling into four general themes.
Inclusion/Exclusion of Relevant Comparators
Guidelines on good modeling practice advocate the use of a
broad range of feasible, mutually exclusive strategies [27]. The
selection of comparators should be informed by current evidence
or opinion and, if relevant, should include a “do nothing” strat-
egy [27]. In reality, the choice of comparators is often governed
by the scope of the model, and rarely are all possible comparisons
made. New comparators can, however, become available during
the analysis period such as in the model by Robinson et al. [26].
This is often the case where unlicensed comparators that exist are
currently seeking approval for use and, as such, will potentially
become valid comparators in the near future.
Inclusion/Exclusion of Relevant Events
All decision models are simpliﬁcations [28] of an actual disease
and health-care consumption process. However, the process of
simpliﬁcation will inevitably require certain assumptions to be
made, for example, the extent to which potential events can be
ignored because they are unlikely to differ between interventions.
A key part of the development of any model is the decision about
which events and health states should be included or excluded
from the model and the effect that treatment will have on these
events and states. In the models by Jones et al. [19] and Steven-
son et al. [23], events previously thought to be unrelated to
treatment were later included in a sensitivity analysis, with
noticeable impacts on estimates of cost-effectiveness.
Statistical Models Used to Estimate Speciﬁc Parameters
Decision models are using increasingly sophisticated statistical
techniques to derive estimates of parameters. This increased com-
plexity can introduce statistical uncertainties [29]. For example,
the models by Berry et al. [15] and Wilson et al. [24] explore
alternative methods to correlate parameters within a model,
where clinical evidence suggests a dependence between param-
eters but there is a lack of data on the exact relationships.
Clinical Uncertainty or Lack of Clinical Evidence
In many situations, a decision model may be commissioned on
the basis of a lack of clinical evidence (in particular, randomized
controlled trial (RCT) evidence) to inform a decision. Even when
RCT evidence is available, there may be an absence of evidence
about key parameters such as treatment effect [20,22], event
rates [25], clinical pathways [14], interaction between model
parameters [18], and clinical practice norms [21,22]. In these
circumstances, assumptions are commonly made, sometimes
based on expert opinion. Often, scenarios are presented based on
alternative but extreme assumptions that could be made [17].
Existing Methods to Characterize Other
Sources of Uncertainty
Of the 13 HTA reports reviewed, two did not attempt to char-
acterize the other sources of uncertainty which where observed
[16,17]. Of the remaining 11 reports, methods were limited to
running alternative scenarios. This requires the analyst to
compute results for each alternative model speciﬁcation [30],
representing alternative sets of judgments and assumptions that
are possible. If only one scenario is regarded as credible and all
others can be disregarded, the parameter uncertainty captures
all the uncertainties surrounding the decision. More commonly,
one scenario may be regarded as most credible but others
cannot be disregarded—there is uncertainty about costs and
effects, given a particular set of judgments and also uncertainty
about which set of judgments might be realized. Parameter
uncertainty no longer represents all the uncertainty surrounding
the decision and the decision-maker must implicitly weigh these
different scenarios to come to a view about cost, effect, and
decision uncertainty. Although the expected costs and outcomes
will be weighted average across credible scenarios, the decision
uncertainty and value of information will not. Of course, when
different credible scenarios suggest different decisions, the struc-
tural uncertainty clearly matters. However, even when this does
not occur, it will affect decision uncertainty and value of infor-
mation too, in ways that are difﬁcult to assess implicitly and
intuitively. In addition, it is not clear which and how many
scenarios should be presented, nor is it possible to establish the
value of conducting further research to resolve the source of
these structural uncertainties.
Given the limitations of scenario analysis, a second systematic
review was undertaken to identify alternative methods [9]. The
purpose of the review was to ﬁnd methods which explore the
types of structural uncertainties identiﬁed in the ﬁrst review, in a
quantiﬁable and explicit manner [31]. As very little on structural
uncertainty has been published in the health economics litera-
ture, searches were not restricted to medical or economics data-
bases. Further details of the search methods, including a
summary of the papers, are available elsewhere [9].
The review identiﬁed 44 potentially relevant papers, the large
majority of which were from the ﬁelds of mathematics and
statistics. The review showed that methods to characterize struc-
tural uncertainties are of two types.
Model Selection
Model selection involves ranking alternative models according to
some measure of prediction performance, goodness of ﬁt or
probability of error [32], and then choosing the model that
maximizes that particular criterion [33–35]. Methods to assesses
performance that have been used previously include Residual
Mean Squared Error, Finite-Prediction-Error [36], minimum
variance criteria [37], and subjective probabilities [38,39].
In HTA decision modeling, where there are many competing
objectives, it is often not possible to identify one particular
parameter whose performance must be maximized by a ﬁtted
model. For those models, in which it is possible to identify a
parameter to optimize, model selection can be difﬁcult given the
limited supply of data [38], which is often the driving force for
the development of a decision model. In addition, it is not always
advantageous to choose the best model as this will discard infor-
mation on other alternative models [40]. Discarding information
from other plausible models will underestimate uncertainty and
generate inaccurate estimates of the value of further research. For
these reasons, model selection is not a plausible method to
740 Bojke et al.
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characterize the types of structural uncertainties observed in the
review of HTA decision models.
Averaging across Potential Models
Model averaging [41] involves building alternative models, with
different structural assumptions representing alternative sets of
judgments, and averaging their results, weighted by some
measure of their adequacy or credibility [42]. Models can be
assigned equal weights, or differential weights can be determined
using either ranking measures akin to those used for model
selection or derived using expert elicitation methods.
Bayesian methods for model averaging (BMA) are commonly
used in mathematics and statistics [43]. The problem of averag-
ing across models can be viewed in a Bayesian sense as one in
which a decision-maker needs to make the best possible use of
information on a model structure he/she has available [44].
When applying BMA [45,46] techniques to HTA decision
models, however, there is the difﬁculty of determining the poste-
rior distribution of a parameter, given the data, when data may
not be available. Non-Bayesian approaches calculate the mean
result of all possible models, weighted by the likelihood that
particular model speciﬁcations are correct [47]. However, in the
absence of data to inform the likelihood or a posterior, the
probabilities assigned represent the prior belief or credibility of
each model. A mean result weighted by prior probabilities can
then be presented.
Although this type of model (or scenario) averaging at an
aggregate level does provide an appropriate measure of expected
costs and quality adjusted life years (QALYs) (they are a simple
weighted average) it cannot appropriately represent the decision
uncertainty or value of information. However, uncertainty both
within and across the alternative models (scenarios) must be
captured. Therefore, model averaging must be undertaken
repeatedly for each realization of the uncertainty within each
model or scenario, i.e., for each iteration of a Monte Carlo. The
possible realizations of both these sources of uncertainty provide
expected costs, QALYs, summary measures of overall decision
uncertainty, and expected value of information [9].
Parameterizing Other Sources of Uncertainty
The sources of uncertainty which contribute to structural uncer-
tainty can be characterized using another approach that is not
identiﬁed in the review. The assumptions that distinguish differ-
ent models or scenarios can often be thought of as either missing
parameters or parameters assigned a single and often extreme
value (equally, alternative models can be thought of as a special
case of a general meta-model). Therefore, by generalizing the
model by including additional “uncertain” parameters, the
source of structural uncertainty can be represented directly in
the analysis. This approach is analogous to model averaging on
individual or sets of model inputs [47].
The method is straightforward to implement within a deci-
sion analytic modeling framework. In order to incorporate the
choice between different structural assumptions, “uncertain”
parameters are added to the model. These uncertain parameters
can be speciﬁed using a number of different distributions,
depending on what prior information is available. Like model
averaging, these distributions can imply equal or unequal weights
for the alternative scenarios. However, unlike model averaging,
where the objective is purely to synthesize all evidence on the
structure of a decision model to assess mean cost and QALYs, by
parameterizing the uncertainty directly in the model, inferences
about the value of further research on the source of uncertainty
can also be made [3,5,48].
Application of Methods
Methods to characterize structural uncertainties have been iden-
tiﬁed and described above. The pertinent issue remains, can these
methods be used to characterize the types of structural uncertain-
ties found in the review of HTA models?
Model selection is not appropriate in HTA decision models
for the reasons described above; however, model averaging and
parameterization are potentially useful. In order to assess the
feasibility and usefulness of the various methods (compared with
scenario analysis), we have applied them to four case study
models. These models are: screening for age-related macular
degeneration (AMD), clopidogrel for prevention of occlusive
vascular events (CLOP), glycoproteins for acute coronary syn-
dromes (GLYCO), and screening for oral cancer (OC). These
case studies were chosen as they each demonstrate one of the four
types of uncertainties described above and were available in
electronic form to the authors.
The implications of each of the methods to characterize struc-
tural uncertainty on cost-effectiveness, decision uncertainty
(probability that each strategy is cost-effective or p[c/e]) and EVI
(at a threshold of £30,000 per QALY) for each case study is
discussed in the sections below.
Case-Study 1: AMD Model
Amodel was developed for the National Coordinating Centre for
Health Technology Assessment to inform the decision to com-
mission further research on the issue of screening for second-eye
AMD [17]. The model evaluated the use of a weekly self-screen
(and subsequent self-referal) using an Amsler grid, followed by
treatment of eligible AMD with photodynamic therapy (PDT;
strategy 1) with two alternative strategies: no screen but treat-
ment of eligible AMD (identiﬁed through self-referral because of
visual acuity [VA] loss) with PDT (strategy 2), and no screen and
no treatment (strategy 3). The population was composed of
males and females, aged 55 years who had previously been
diagnosed with ﬁrst-eye involvement with neovascular AMD.
The model was run for two starting VAs, 20/40 and 20/80. The
20/40 model is used for illustration here.
A Markov process [49] is used to model the incidence of
second-eye neovascular AMD for over 10 years and the associ-
ated decline in VA following undiagnosed second-eye involve-
ment. Full details of this model are reported elsewhere [17].
Observed structural uncertainty in the AMD model. The effect
of the Amsler grid, in terms of identifying patients with AMD,
can occur before VA loss and at each stage of VA loss [17].
However, it is also clinically plausible that there is no additional
beneﬁt from the Amsler grid after a patient has developed a VA
problem (after a loss of one or more lines) and that patients will
only self-refer because they have noted this loss in VA.
In addition, the original model assumed that only at a loss of
four or more lines, will all patients self-refer to the ophthalmolo-
gist, and that at a loss of less than four lines only a proportion of
patients self-refer. It is possible that all patients (not just a pro-
portion) will refer to see an ophthalmologist once they have any
decline in VA; that is, all patients self-refer (100%) after a loss of
only one line. This alternative assumption is plausible, given that
patients in the model have already had ﬁrst-eye involvement and
may, therefore, be expected to be more vigilant in recognizing
changes in their vision.
Three scenarios are, therefore, possible for the model: sce-
nario 1, Amsler grid provides additional beneﬁt after a loss in VA
and the number of patients self-referring depends on the extent of
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VA loss; scenario 2, Amsler grid provides no additional beneﬁt
after a loss in VA and the number of patients self-referring
depends on the extent of VA loss; and scenario 3, all patients will
self-refer after a loss in visual acuity of one line (irrespective of
Amsler grid performance as all patients self-referring after a loss
in VA supersedes the performance of the Amsler grid). The results
of the three scenarios are shown in Table 2.
Changing the assumption of the additive effect of the Amsler
grid and the number of people self-referring, had little effect on the
mean costs and QALYs and the resulting estimates of the ICER.
Screening is still regarded as cost-effectivewhen comparedwith no
treatment, as long as decision-makers are willing to pay £16,177
for an additional QALY. This is because the majority of patients
are diagnosed through the self-screen before any loss in VA.
Decision uncertainty is however sensitive to structural assump-
tions, with the probability that screening and treatment is cost
effective reduced from 0.94 in scenario 1 to 0.74 in scenario 3.
The population EVI for the alternative scenarios is markedly
different, ranging from £260,000 in scenario 1 to £18.4 million
in scenario 3 at a threshold of £30,000. The value associated
with speciﬁc groups of parameters, for all scenarios, were also
calculated. In scenario 1, the value of information associated
with the expected QALYs with or without PDT is £120,000. The
other groups of model inputs such as screening accuracy have no
value of information associated with them.
Applying methods to characterize uncertainty in AMD model.
For model averaging, the choice of prior or weight given to each
of the three scenarios in the AMD model was not informed by
expert opinion in this instance; therefore, equal weights (imply-
ing equal plausibility) have been applied to each scenario.
The possible outcomes for the three scenarios can also be
presented as a choice between alternative and plausible values for
new uncertain parameters (parameterized). The model is then
run as before. EVI for these uncertain parameters can also be
calculated. Two uncertain parameters were therefore added to
the AMD model: 1) the Amsler grid works beyond a loss in VA
or it does not; and 2) all patients self-refer after a loss in VA or
only a proportion self-refer. In principle, expert opinion could be
elicited to obtain prior distributions for the uncertain parameters
[50]. For illustration purposes here, a beta distribution is used to
represent the uncertain parameters; however, other distributions
may also be appropriate. The beta distribution is used here as it
is frequently used to parameterize probabilities in decision ana-
lytic models and is deﬁned in the 0–1 interval [6]. As no prior
knowledge on the weights that should be attached to each sce-
nario was available, a 50–50 chance was assumed for each sce-
nario in each of the uncertain parameters. The parameters of the
beta distribution were alpha = 0.5, beta = 0.5.
For uncertain parameter 1, values sampled from the param-
eters that fall below 0.5 indicate that the Amsler grid works
beyond a loss in VA and values above 0.5 indicate that the
Amsler grid does not work beyond a loss in visual acuity. For
uncertain parameter 2, values sampled from the parameters that
fall below 0.5 indicate that all patients self-refer following a loss
in VA and values above 0.5 indicate that the number of patients
self-referring is proportional to the extent of VA loss. Although
there are four scenarios implied by the choice between the two
uncertain parameters, as stated previously, all patients self-
referring supersedes the Amsler grid not working beyond any loss
in VA; thus, only three scenarios are possible from the two
uncertain parameters.
Results: AMD model. The results for the model averaging and
parameterizing can also be seen in Table 2. Averaging across the
three scenarios does not change the adoption decision; that is,
screening is still regarded as cost-effective when compared with
no treatment using this approach. We are also fairly certain about
screening being cost-effective. However, although the adoption
decision remains unaffected, the level of decision uncertainty
appears somewhat sensitive to structural assumptions, with the
probability that screening plus treatment is cost-effective reduced
from 0.94 in the base case model to 0.83 when averaging across
the 3 scenarios. In the averaging model, EVI increases as com-
pared with scenario 1 to over £9 million with the greatest value
associated with QALY parameters.
By including speciﬁc parameters to represent the uncertainty
about the effect of the Amsler grid and the probabilities of
self-referral (parameterizing), the ICER is slightly higher than
scenario 1 (£14,106 compared with £12,892 per additional
QALY). The adoption decision again remains unchanged, that is,
screening still appears to be cost-effective (probability = 0.78).
Table 2 Results for Age-Related Macular model
Strategy QALYs Costs ICER P(c/e) £30k EVI
Scenario 1
Strategy 1: Screen and treat 1.22 £3,653 £12,755 0.94 £260,913
Strategy 2: No screen and treat 0.98 £2,640 E dominated 0
Strategy 3: No screen and no treat 0.94 £98 — 0.06
Scenario 2
Strategy 1: Screen and treat 1.22 £3,668 £12,764 0.92 £936,240 mil
Strategy 2: No screen and treat 0.98 £2,645 E dominated 0.03
Strategy 3: No screen and no treat 0.94 £98 — 0.12
Scenario 3
Strategy 1: Screen and treat 1.22 £3,662 £16,177 0.74 £18.4 mil
Strategy 2: No screen and treat 1.06 £2,741 E dominated 0.01
Strategy 3: No screen and no treat 1.00 £98 — 0.25
Model averaging
Strategy 1: Screen and treat 1.22 £3,656 £13,682 0.83 £9 mil
Strategy 2: No screen and treat 1.01 £2,678 E dominated 0.02
Strategy 3: No screen and no treat 0.96 £98 — 0.12
Parameterizing
Strategy 1: Screen and treat 1.2116 £3,648 £14,106 0.78 £19 mil
Strategy 2: No screen and treat 1.0158 £2,674 E dominated 0.08
Strategy 3: No screen and no treat 0.9599 £98.09 — 0.15
EVI, expected value of information; ICER, incremental cost-effectiveness ratio; mil, million; P(c/e); probability that each strategy is cost-effective.
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This increase in decision uncertainty means that EVI increases to
nearly £19 million. Partial EVI again showed that the greatest
value of information was associated with the parameters looking
at QALYs with or without PDT. Partial EVI was also calculated
for the two uncertain parameters (the effect of the Amsler grid
and the self-referral rates with any loss in VA) added to the
parameterizing model; however neither was associated with any
value.
Case study 2: CLOP model
One of the four models developed to inform the National Insti-
tute for Clinical Excellence appraisal of clopidogrel and
modiﬁed-release (MR)-dipyridamole, for the secondary preven-
tion of occlusive vascular events [51], is included here. The model
looks at the coeffectiveness of clopidogrel and MR-dipyridamole
for patients with stroke [19]. Further details of this model and
the other three models included in the appraisal can be found
elsewhere [19].
Four treatment strategies were considered: strategy 1, treat-
ment with aspirin over a lifetime; strategy 2, treatment with
clopidogrel over a lifetime; strategy 3, treatment with aspirin and
MR-dipyridamole over a lifetime; and strategy 4, treatment with
MR-dipyridamole over a lifetime.
Observed structural uncertainty in the CLOP model. For stroke
patients, deaths can be caused by vascular and nonvascular
events. Given that the treatments are expected to impact on the
rates of vascular deaths, it would seem logical to only include
vascular deaths as an outcome; however, rates of nonvascular
deaths also appeared to differ quite substantially between treat-
ments. The effect of treatment on nonvascular death was not
originally speciﬁed as an outcome of interest. Two alternative
scenarios are therefore possible for the model: scenario 1, exclud-
ing the effect of treatment on nonvascular deaths; and scenario 2,
including the effect of treatment on nonvascular deaths. The
results of the two scenarios are shown in Table 3.
Including the effect of vascular deaths has an important
impact on the cost-effectiveness results. Strategy 3 is the most
cost-effective treatment in scenario 1, as long as decision-
makers are willing to pay £27,294 for an additional QALY. In
scenario 2, however, strategy 1 dominates all other strategies.
The change in adoption decision is because of the higher
number of nonvascular deaths in strategy 3 compared with
strategy 1 (relative risk (RR) = 1.062). If nonvascular deaths
are included in the model, strategy 3 is no longer considered
cost-effective, and instead strategy 1 is the preferred treatment
(most cost-effective). Decision uncertainty is also affected by the
inclusion or exclusion of vascular deaths. The probability that
strategy 3 is the most cost-effective strategy, at a threshold of
£30,000 per QALY, decreases from 0.579 in scenario 1 to
0.308 in scenario 2. Because of the increase in decision uncer-
tainty moving from scenario 1 to scenario 2, the EVI for the
whole model increases from £2.4 billion to £9 billion.
Calculating the EVI associated with particular parameters
showed that in scenario 1, further research on the risk of events
(myocardial infarction [MI], stroke, percutaneous coronary
intervention [PCI], and coronary artery bypass graft [CABG]) is
worthwhile at over £1.45 billion. All other parameters were
associated with little or no value. In scenario 2, the greatest value
is associated with further research on the relative risks of events,
at over £8 billion.
Applying methods to characterize uncertainty in the CLOP
model. Model averaging is again conducted by taking the
mean estimate of total costs and QALYs for each strategy at each
iteration of the CLOP model. Equal weights were applied to each
scenario in the CLOP model.
The inclusion or exclusion of events in the CLOP model can
be represented by an uncertain parameter with a prior distribu-
tion. In the absence of expert opinion, the uncertain parameter
was again speciﬁed as a beta distribution. Sampled values below
0.5 where taken to indicate that the events should be included,
and values above 0.5 indicating that the events should be
excluded. EVI for the uncertain parameter is also calculated.
Results: CLOP model. The results for model averaging and
parameterizing are also shown in Table 3. Strategy 1 is the most
cost-effective option when using model averaging to characterize
structural uncertainty. Strategies 3 and 4 are again dominated
and strategy 2 is unlikely to be considered cost-effective with an
ICER of £240,084. Strategy 1 has a probability of being cost-
effective of 0.426 in the averaging model compared with 0.046 in
scenario 1 and 0.337 in scenario 2, at a threshold of £30,000 per
Table 3 Results for clopidogrel for prevention of occlusive vascular events model
Strategy QALYs Cost ICER P(c/e) £30k EVI
Scenario 1
Strategy 1:Aspirin 9.756 £30,577 — 0.046 £2.4 bil
Strategy 2: Clopidogrel 9.893 £38,145 £76,068 0.150
Strategy 3:Aspirin and MR-dip 9.815 £32,198 £27,294 0.579
Strategy 4: MR-dip 9.640 £32,074 Dominated 0.225
Scenario 2
Strategy 1:Aspirin 9.778 £30,343 — 0.337 £9 bil
Strategy 2: Clopidogrel 9.704 £37,577 Dominated 0.019
Strategy 3:Aspirin and MR-dip 9.672 £31,687 Dominated 0.308
Strategy 4: MR-dip 9.705 £31,882 Dominated 0.336
Model averaging
Strategy 1:Aspirin 9.773 £30,425 — 0.426 £4 bil
Strategy 2: Clopidogrel 9.804 £37,822 £240,084 0.006
Strategy 3:Aspirin and MR-dip 9.746 £31,898 Dominated 0.331
Strategy 4: MR-dip 9.675 £31,935 Dominated 0.237
Parameterizing
Strategy 1:Aspirin 9.709 £29,289 — 0.388 £5.9 bil
Strategy 2: Clopidogrel 9.687 £36,925 Dominated 0.022
Strategy 3:Aspirin and MR-dip 9.350 £30,831 Dominated 0.166
Strategy 4: MR-dip 9.654 £30,979 Dominated 0.424
EVI, expected value of information; ICER, incremental cost-effectiveness ratio; bil, billion; P(c/e); probability that each strategy is cost-effective.
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QALY. EVI is again high in the averaging model at over £4
billion. Again, the greatest value was associated with parameters
relating to the relative risks of events at over £2.9 billion.
Parameterizing structural uncertainty in the stroke model
produced similar results to the averaging model. Strategy 1 domi-
nates all other strategies; however, the adoption decision is very
uncertain (probability = 0.38). The high degree of decision un-
certainty in the parameterizing model leads to a high value of
conducting further research at £5.86 billion. Quantifying the risk
of vascular events would offer the highest returns to research at
£4.02 billion; within this, the relative risks of vascular and non-
vascular mortality offer the highest return to research at £3.65
billion. The EVI for the new uncertain parameter was also cal-
culated for the parameterizing models. This suggests that there is
value in commissioning further research to reduce this structural
uncertainty (over £800 million).
Case Study 3: GLYCO Model
A decision-analytic model was developed to assess the cost-
effectiveness of GPA IIb/IIIa antagonists (GPAs; abciximab, epti-
fabtide, and tiroﬁban) and no GPA for the treatment of patients
with nonsegment (non-ST) elevation acute coronary syndromes
(ACS) [52]. A sensitivity analysis including the use of clopidogrel
as a ﬁfth strategy was also undertaken. The model was con-
structed in two parts—a short-term and long-term part [52]. The
short-term decision model tracks patients through various
ischemic events over an initial 6-month period. The long-term
Markov model estimates prognosis for patients who ﬁnish the
short-term (6 months) model in one of the two alive states [52].
GPAs work to reduce the risk of events during the initial 6-month
period which are then translated into differences in long-term
costs and QALYs on the basis of the long-term model.
A separate model was developed to assess the cost-
effectiveness of clopidogrel in combination with aspirin versus
aspirin alone [20]. A sensitivity analysis was also carried out
exploring alternative durations for clopidogrel (1-month,
3-months, 6-months, and 12-months). This model did not
include GPA as a comparator. The clopidogrel model utilized the
same short-term and long-term model structures. The clopidogrel
model used the short-term model for a 12-month period follow-
ing ACS. Clopidogrel is assumed to work in the same way as
GPAs, that is, to reduce the risk of death or non-fatal MI. Further
details of both models are available elsewhere [20,52].
Observed structural uncertainty in the GPA model. The original
model scopes deﬁned the initial interventions of interest as GPAs
versus standard care and clopidogrel versus standard care. It is
not clear what the optimal strategy would be if all the strategies
were compared simultaneously. An alternative model therefore
exists with all eight GPA and clopidogrel strategies.
The new model uses the clopidogrel model structure and adds
the four GPA strategies (standard care, GPAs as part of medical
management, GPAs for planned PCI [<72 hours], and GPAs for
those undergoing PCI (<1 hour). Three scenarios are therefore
possible: 1) clopidogrel is not a relevant comparator for the
model; 2) GPAs are not a relevant comparator; and 3) GPA
strategies + four clopidogrel strategies. The results for the three
scenarios are shown in Table 4.
In scenario 1, GPAs in medical management (strategy 2)
represents the most cost-effective strategy (ICER = £5769) All
other strategies are dominated or extendedly dominated. The
decision to recommend GPAs in medical management as the
preferred strategy is, however, uncertain at 0.71. Clopidogrel
(strategy 5) is extendedly dominated (ICER = £6008) and there is
a 0.27 probability that it is cost-effective at a threshold of
£30,000.
In scenario 2, clopidogrel given for 3-months and 6-months
are ruled out because of extended dominance. Clopidogrel given
for 12-months (strategy 5) is the most cost-effective strategy
(ICER = £5159) so long as the decision-makers’ willingness to
pay threshold is above this value. The decision to recommend
clopidogrel as the most cost-effective strategy is less uncertain
than the adoption decision for scenario 1. The probability that
clopidogrel treatment for 12-months represents the most cost-
effective treatment is fairly certain at 0.83.
Incorporating all the strategies into a single model (scenario
3) changes the adoption decision. All the clopidogrel strategies
and standard care are excluded on the basis that they are domi-
nated by GPAs used as part of medical management (strategy 2).
If a decision-maker’s threshold willingness to pay is above £4095
then GPAs given less than 1 hour before a planned PCI represent
Table 4 Results for GP antagonists model
Strategy QALYs Costs ICER P(c/e) £30k EVI
Scenario 1
Strategy 1: Standard care 7.663 £12,216 — 0 £184 mil
Strategy 2: GPAs in medical management 7.763 £12,790 £5,769 0.71
Strategy 3: GPAs in planned PCI 7.659 £12,307 D 0
Strategy 4: GPAs in those undergoing PCI 7.666 £12,287 ED 0.01
Strategy 5: Clopidogrel 7.717 £12,594 ED 0.27
Scenario 2
Strategy 1: Standard care 8.268 £12,549 — 0.11 £136 mil
Strategy 5: Clopidogrel for 1 year 8.385 £13,044 £5,159 0.83
Strategy 6: Clopidogrel for 6 months 8.322 £12,762 ED 0
Strategy 7: Clopidogrel for 3 months 8.306 £12,647 ED 0
Strategy 8: Clopidogrel for 1 month 8.293 £12,570 £824 0.06
Scenario 3
Strategy 1: Standard care 8.323 £12,657 D 0 £232 mil
Strategy 2: GPAs in medical management 8.401 £12,459 £1,939 0.08
Strategy 3: GPAs in planned PCI 8.126 £11,913 — 0.11
Strategy 4: GPAs in those undergoing PCI 8.489 £12,819 £4,095 0.75
Strategy 5: Clopidogrel for 1 month 8.352 £12,682 D 0
Strategy 6: Clopidogrel for 3 months 8.366 £12,760 D 0
Strategy 7: Clopidogrel for 6 months 8.383 £12,877 D 0
Strategy 8: Clopidogrel for 1 year 8.399 £13,099 D 0.06
D, dominated; ED, extendedly dominated; EVI, expected value of information; ICER, incremental cost-effectiveness ratio; mil, million; P(c/e); probability that each strategy is cost-effective.
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the most cost-effective strategy. This change of preferred GPA
strategy, compared with scenario 1, is because the next best
strategy (for the purposes of calculating the ICER) changes. The
decision to adopt GPAs given less than 1 hour before planned
PCI as the most cost-effective strategy is somewhat uncertain at
0.75. The probability that either of the clopidogrel strategies are
the most cost-effective are approximately zero, which contrasts
with the conclusions regarding the cost-effectiveness of the clo-
pidogrel strategy included in the GPA model.
Because of the high level of decision uncertainty, scenario 1
produced high EVI results at over £184 million at a threshold of
£30,000 and a 10-year lifetime of the technology. Partial EVI
suggests that further research would be best focused on deter-
mining the relative risk of events for the GPAs in medical man-
agement strategy (£74 million) and the relative risk of events in
the clopidogrel strategy (52 million).
The EVI estimate for scenario 2 reﬂects the fact that there is
less uncertainty compared with scenario 1. However, total EVI is
still £136 million, suggesting that further research may be valu-
able. Partial EVI for scenario 2 also showed that further research
should focus on producing better estimates of the relative risks
associated with the short-term model, speciﬁcally the relative risk
of mortality (£17 million) and relative risk of MI (£69 million).
Total EVI is substantial in scenario 3 at £232 million. Partial
EVI for scenario 3 suggests that, like the GPA and clopidogrel
models, the focus of further research should be on obtaining
better estimates of the relative risks of events in the short-term
model. The relative risk of MI was associated with the highest
value at £111 million followed by the relative risk of mortality at
£93 million.
Applying methods to characterize uncertainty in the GPA
model. It was not possible nor would it be appropriate to model
average or parameterize this type of structural uncertainty
directly in the model for two reasons. Firstly, this structural issue
implies a different ordering of comparators in terms of cost-
effectiveness. To average across these would therefore be nonsen-
sical as zero costs and QALYs are observed for the clopidogrel
strategies in scenario 1 and GPA strategies in scenario 2. Sec-
ondly, this is really a choice that must be made (and justiﬁed)
rather then actual uncertainty about what the appropriate com-
parators ought to be. In general, any comparator should be
included in the analysis if it has some probability of being cost-
effective (it contributes to decision uncertainty and value of infor-
mation even if it is not regarded as cost-effective) unless there are
legitimate reasons to exclude it e.g., if it is not licensed for use. If
alternatives are excluded for other reasons such as side effects,
difﬁculty of administration, and risk of resistance, then this sug-
gests that important aspects of cost and outcome have been
excluded from the analysis. Only results for the scenario analysis
are therefore presented for this type of uncertainty.
Case Study 4: OC Model
A probabilistic model was developed to compare the cost-
effectiveness of no screening with a range of alternative screening
strategies for oral cancer, based on a one-off prevalence screen,
including invitational and opportunistic programs undertaken in
both primary medical and dental locations [53]. A lifetime per-
spective was used. Full details of this model are available else-
where [53].
Eight different screening strategies were modeled: 1) no
screening; 2) invitational screening (general medical practice
[GMP]); 3) invitational screening (general dental practice
[GDP]); 4) opportunistic screening (GMP); 5) opportunistic
screening (GDP); 6) opportunistic “high-risk” screening (GMP);
7) opportunistic “high-risk” screening using a neural network
(GMP); 8) invitational screening (secondary care).
A Markov process is used to model the prevalence of undi-
agnosed oral precancer and cancer in the general population.
Patients may be diagnosed with precancer and cancer either via
self-referral/routine case ﬁnding or, for the screening strategies,
as part of the formal screening program. Patients who are diag-
nosed with precancer or cancer enter a long-term prognosis
model. Expected survival duration, quality of life, and associated
costs of treatment for oral cancer are assumed to depend on the
stage at diagnosis. Survival analysis methods were applied to
cancer registry data in order to calculate the transition probabili-
ties required for the prognosis model.
Observed structural uncertainty in the OC model. In the base
case model, survival was modeled as a Weibull distribution (after
excluding the possibility of a constant hazard). Other alternatives
to the Weibull distribution were initially not explored; however,
other distributions may also be feasible [54].
The Gompertz model is another generalization of the expo-
nential distribution [55] and like the exponential and Weibull
distributions, it has the property of proportional hazards [54].
Two scenarios are therefore possible: 1) survival follows a
Weibull distribution; and 2) survival follows a Gompertz distri-
bution. The results for these two scenarios are shown in Table 5.
If a Weibull distribution (scenario 1) for survival of diagnosed
patients is assumed, strategies 4 (opportunistic screening by the
GP), 7 (opportunistic screening of high-*risk groups by a GP),
and 8 (opportunistic screening using a neural network by a GP)
all have similar ICERs at £23,237, £23,370, and £25,359,
respectively (Table 5). Presuming a decision-maker’s willingness
to pay threshold is above £25,359, strategy 8 is likely to be
regarded as the most cost-effective strategy, given that it is asso-
ciated with the highest number of QALYs. The uncertainty sur-
rounding this decision is high, with only a 0.488 probability that
strategy 8 is the most cost-effective at a threshold willingness to
pay of £30,0000.
In contrast, if a Gompertz distribution (scenario 2) for sur-
vival of diagnosed patients is assumed (scenario 2), strategy 8 is
dominated and strategies 4 and 7 have ICERs above £40,000
(£42,986 and £41,177, respectively). Unless a decision-maker’s
threshold is above £40,000, it is unlikely that these would be
regarded as cost-effective. If the threshold is below £40,000,
strategy 1 (no screening) would be considered the preferred strat-
egy. Decision uncertainty (at a threshold of £30,000) is much less
in scenario 2 at 0.719 compared with 0.488 for the preferred
strategy.
The EVI values reﬂect the differences in the decision uncer-
tainty described above. For scenario 1, total EVI is substantial at
£2.3 million. We are less uncertain about the decision in scenario
2, which this leads to a lower total EVI ﬁgure at £1.6 million.
Partial EVI showed that many of the uncertain parameters in the
model were associated with positive values. It is probably rea-
sonable to suggest that quantifying the probability that undiag-
nosed patients progress (£1.8 million in scenario 1, £1.1 million
in scenario 2) should be high on the list of priorities for further
research. The set of parameters the Weibull survival model was
used to populate (survival for diagnosed patients) appear to be
less important with a value of £43,000 in the two scenarios,
suggesting that further research is unlikely to be cost-effective.
Applying methods to characterize uncertainty in the OC
model. Model averaging is again conducted by taking the mean
estimate of total costs and QALYs for each strategy at each
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iteration of the OC model. Equal weights were applied to each
scenario in the OC model.
The choice of survival model in the OC model can be repre-
sented by an uncertain parameter with a prior distribution. In the
absence of expert opinion, the uncertain parameter was again
speciﬁed as a beta distribution. Sampled values below 0.5 where
taken to indicate that survival should follow a Weibull distribu-
tion, and values above 0.5 indicate that survival should follow a
Gompertz distribution. EVI for this uncertain parameter is also
calculated.
Results: OC model. The results for model averaging and param-
eterizing in the OC model are also shown in Table 5; by averag-
ing across the two scenarios, the preferred strategy changes. At a
threshold of £30,000 is strategy 3 and is likely to be cost-effective
(invitational screening by GMP), with an ICER of £3246 com-
pared with strategy 1. The uncertainty surrounding this decision
is high, with a 0.5276 probability that strategy 3 is the most
cost-effective. In the averaging model, strategies that are domi-
nated show a non-zero probability of being cost-effective because
of the high degree of skew ness in costs and outcomes. EVI is
substantial in the averaging model at £18 million. Partial EVI
analysis suggests that the focus should be on parameters relating
to the probability that undiagnosed patients will progress (£12.1
million).
The adoption decision also changes when parameterizing the
uncertainty. At a threshold value of £30,000 per QALY, strategy
6 (opportunistic screening of high-risk groups by a GP) is likely
to be considered cost-effective with an ICER of £29,030. There is
a great deal of uncertainty associated with this decision, with
only a 0.0338 probability that strategy 6 is cost-effective. Other
strategies with higher ICERs are actually associated with a higher
probability of being cost-effective because of the extreme skew-
ness in costs and QALYs in the parameterizing model. EVI is
much less in the parameterizing model, compared with the aver-
aging model (£2.93 million compared with £18 million), because
the consequences of making the wrong decision (in terms of lost
QALYs) are much greater in the averaging model despite the
increased decision uncertainty in the parameterizing model.
Like the scenarios, partial EVI showed that the greatest value
of research was associated with parameters relating to progres-
sion for undiagnosed patients (£2.4 million). In the parameteriz-
ing model, it is also possible to conduct EVI for the uncertain
beta parameter, representing the uncertainty between the choice
of survival models. This was not of any signiﬁcant value (in
relation to the likely cost of research) at £13,964.
Discussion
The characterization of uncertainty is critical in cost-effectiveness
analysis, particularly when the decision-maker must consider
whether additional evidence is needed. There are a number
of sources of uncertainty relevant to estimating the cost-
effectiveness of a particular intervention of which uncertainty
about parameter estimates is only one. Other and potentially
more important sources of uncertainty include the different types
of simpliﬁcations and scientiﬁc judgments that have to be made
when constructing and interpreting a model of any sort. These
Table 5 Results for oral cancer model
Strategy QALYs Costs ICER P(c/e) £30k EVI
Scenario 1
Strategy 1: No screen 13.054 £41.12 — 0.4456 £2.3 mil
Strategy 2: Invitational screen (GMP) 13.055 £59.43 ED 0
Strategy 3: Invitational screen (GDP) 13.056 £90.26 ED 0
Strategy 4: Opportunistic screen (GMP) 13.057 £100.37 £23,237 0.0018
Strategy 5: Opportunistic screen (GDP) 13.057 £116.00 ED 0
Strategy 6: opportunistic high risk screen (GMP) 13.056 £117.74 D 0
Strategy 7: Opportunistic high risk screen (GDP) 13.059 £156.11 £23,370 0.0644
Strategy 8: Invitational screen 13.060 £186.80 £25,359 0.4882
Scenario 2
Strategy 1: No screen 12.996 £53.42 — 0.7196 £1.6 mil
Strategy 2: Invitational screen (GMP) 12.997 £123.51 ED 0
Strategy 3: Invitational screen (GDP) 12.996 £79.82 ED 0
Strategy 4: Opportunistic screen (GMP) 13.001 £263.31 £42,986 0.2488
Strategy 5: Opportunistic screen (GDP) 12.998 £164.07 ED 0
Strategy 6: opportunistic high risk screen (GMP) 12.999 £223.16 £41,340 0.0294
Strategy 7: Opportunistic high risk screen (GDP) 12.998 £140.95 £41,177 0.0022
Strategy 8: Invitational screen 12.997 £154.02 D 0
Model averaging
Strategy 1: No screen 12.996 £55.97 — 0.0192 £18 mil
Strategy 2: Invitational screen (GMP) 13.003 £120.56 £33,756 0.0126
Strategy 3: Invitational screen (GDP) 13.002 £76.31 £3,246 0.5276
Strategy 4: Opportunistic screen (GMP) 13.005 £268.11 £70,843 0.0104
Strategy 5: Opportunistic screen (GDP) 13.003 £161.93 D 0
Strategy 6: opportunistic high risk screen (GMP) 12.999 £224.82 D 0.0682
Strategy 7: Opportunistic high risk screen (GDP) 12.998 £141.68 D 0.263
Strategy 8: Invitational screen 12.999 £157.69 D 0.099
Parameterizing
Strategy 1: No screen 12.998 £57.46 — 0.598 £2.9 mil
Strategy 2: Invitational screen (GMP) 13.001 £127.24 ED 0
Strategy 3: Invitational screen (GDP) 12.999 £83.74 ED 0
Strategy 4: Opportunistic screen (GMP) 13.006 £271.13 £30,778 0.3694
Strategy 5: Opportunistic screen (GDP) 13.002 £167.48 ED 0
Strategy 6: opportunistic high risk screen (GMP) 13.004 £226.41 £29,030 0.0312
Strategy 7: Opportunistic high risk screen (GDP) 13.0017 £144.59 £22,062 0.01
Strategy 8: Invitational screen 13.001 £157.73 D 0
D, dominated; ED, extendedly dominated; EVI, expected value of information; ICER, incremental cost-effectiveness ratio; mil, million; P(c/e); probability that each strategy is cost-effective.
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other sources of uncertainty have been classiﬁed in a number of
different ways but can be referred to collectively as structural
uncertainties. Although it is common practice to acknowledge
potential limitations in model structure and highlight the
assumptions and judgments made, there is a lack of clarity about
methods to evaluate structural uncertainties. Methods have gen-
erally been limited to scenario analysis but analysts need to
address the question as to how model uncertainty will affect
forecast accuracy [56] and contribute to overall decision uncer-
tainty. Alternative structural assumptions can produce very dif-
ferent values of additional research estimates and it is therefore
essential—for decision-making purposes—to incorporate issues
of structural uncertainty into the decision modeling process,
thereby representing not only within model uncertainty (param-
eter uncertainty) but also between model uncertainties.
In the AMD model, structural uncertainty had little impact
on the ICER and as a result, the adoption decision did not change
in any of the three scenarios. Despite this, changing the effective-
ness of the Amsler grid and the self referral rates did affect
decision uncertainty and thus EVI (ranging from £940,000 to
£18.4 million). In the CLOP, GPA and OC models model, the
structural uncertainties had a more marked impact on cost-
effectiveness, changing the adoption decision for each scenario,
thus altering the amount of decision uncertainty and the value of
research.
The use of model averaging and parameterization was appro-
priate in three of the four case studies (AMD, CLOP, and OC
models). The method that introduced the most uncertainty and
the highest EVI was different for each of the case-study models as
this was also dependent on if the adoption decision changed and
the degree of uncertainty was associated with the new preferred
strategy.
When assessing the usefulness of the two methods to explic-
itly characterize structural, it is important to recognize that
although we can calculate a single estimate of costs, QALYs,
decision uncertainty, and EVI using model averaging, we cannot
make judgments about the value of conducting further research
on those speciﬁc uncertain parameters. Thus, model averaging
cannot help to inform a decision about the requirement for more
evidence to reduce any structural uncertainties. By explicitly
characterizing these other sources of uncertainty in the model as
measurable parameters, we can quantify the increase in decision
uncertainty and thus value of research directly, helping to inform
a research prioritization process.
In comparing the model averaging and parameterizing tech-
niques, we must also be mindful of any differences in prior
weights applied to the two methods, which can occur when there
are more than two scenarios. This is the case in the AMD model,
where the model averaging models assumes an equal probability
of each of the scenarios, which equates to a 33.3% for each.
However, in the parameterizing method, there is a 50% chance of
scenario 3, and a 25% chance each for scenarios 1 and 2. Thus,
in using what we regard as uninformative priors, we actually
differentially weight scenarios in the case of the AMD model.
Of course, these probability weights should represent the
beliefs of experts or decision-makers. The literature on eliciting
and aggregating expert opinion provides suitable methods to do
this. These techniques are useful for quantifying unknown
parameters in the absence of actual data [57] but can involve
lengthy elicitation procedures and introduce additional model
uncertainties such as the selection of experts and methods of
synthesizing for elicited data [50]. Related to this is the potential
for an almost unlimited number of scenarios, thus requiring a
lengthy elicitation process to derive weights for all possible
scenarios.
Indeed for the AMD, CLOP, and OC models, one may argue
that the fact that the uncertainty regarding the treatment effect
can be parameterized directly in model indicates that this type of
uncertainty is actually parameter rather than structural. Clearly,
it is not always possible to separate out the two types of uncer-
tainty and indeed the use of one-way sensitivity analysis or
scenario analysis is a method applicable to both types. However,
this does raise a further important issue; if this type of uncer-
tainty is not structural, then what exactly is structural uncer-
tainty? It may be that the distinction between parameter and
structural uncertainty is rather false and unhelpful. One could
argue that there is just uncertainty, and making distinctions
about its source is somewhat arbitrary. What has been referred to
as structural uncertainty could simply be regarded as missing
parameters for which little or no evidence exists to inform them.
In these circumstances, judgment is inevitably required whether it
is judgment over which scenarios are most plausible, which prob-
abilities should be assigned in model averaging, or what values
the missing parameters are likely to take. The latter approach
seems most useful as it makes explicit the nature of the judgments
required and the type of experts that might best provide them; it
enables the formal elicitation of parameter values and facilitates
an analysis that is able to inform research decisions about these
uncertainties.
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